Terms: = Uterine cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Staging
10 results:
1. Association of Membranous WNT-1 and Nuclear mtor with Endometrial cancer Grade.
Pietrus M; Pitynski K; Waligora M; Milian-Ciesielska K; Ludwin A; Socha MW; Skrzypek K
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176048
[TBL] [Abstract] [Full Text] [Related]
2. UBE2C Drives Human Cervical cancer Progression and Is Positively Modulated by mtor.
Chiang AJ; Li CJ; Tsui KH; Chang C; Chang YI; Chen LW; Chang TH; Sheu JJ
Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33396624
[TBL] [Abstract] [Full Text] [Related]
3. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
Bendifallah S; Ilenko A; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
[TBL] [Abstract] [Full Text] [Related]
4. Chemotherapy for Endometrial cancer in Adjuvant and Advanced Disease Settings.
Bestvina CM; Fleming GF
Oncologist; 2016 Oct; 21(10):1250-1259. PubMed ID: 27412393
[TBL] [Abstract] [Full Text] [Related]
5. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract] [Full Text] [Related]
6. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Black JD; English DP; Roque DM; Santin AD
Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
[TBL] [Abstract] [Full Text] [Related]
7. Endometrial cancer: molecular and therapeutic aspects.
Tsikouras P; Bouchlariotou S; Vrachnis N; Dafopoulos A; Galazios G; Csorba R; von Tempelhoff GF
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(1):1-9. PubMed ID: 23433742
[TBL] [Abstract] [Full Text] [Related]
8. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract] [Full Text] [Related]
9. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Hayes MP; Douglas W; Ellenson LH
Gynecol Oncol; 2009 Jun; 113(3):370-3. PubMed ID: 19272638
[TBL] [Abstract] [Full Text] [Related]
10. Stage IA1 cervical adenocarcinoma: definition and treatment.
Schorge JO; Lee KR; Flynn CE; Goodman A; Sheets EE
Obstet Gynecol; 1999 Feb; 93(2):219-22. PubMed ID: 9932559
[TBL] [Abstract] [Full Text] [Related]
